Clinical Trial

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell lymphomas. Duvelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-17.
Status change: Not Yet Recruiting → Recruiting 2026-05-29
Trial Details
NCT Number NCT07293403
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Enrollment 25 participants
Start Date 2026-10-01
Primary Completion 2027-11-23 (estimated)
Study Completion 2027-11-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-05